Home Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
Article Open Access

Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report

  • Qiancheng Xu , Tao Wang and Weihua Lu EMAIL logo
Published/Copyright: August 23, 2021

Abstract

Inflammation and coagulation are considered to the development of Coronavirus disease 2019 (COVID-19)-related hypoxemia. However, this is still controversial, which brings challenges to clinical treatment. Here, we reviewed the levels of interleukin-6 (IL-6), coagulation indexes, and clinical manifestations of a patient with severe COVID-19 after Tocilizumab administration. In this case, the patient’s body temperature quickly dropped to normal after using Tocilizumab, while C reactive protein progressively decreased and stabilized at a lower level. However, IL-6 and D-dimers increased and were accompanied by a continuous decrease of the oxygenation index. After anticoagulant therapy with heparin, D-dimer decreased slowly, gradually improving the oxygenation index and disease remission. This case suggests that the formation of microthrombus might be the main reason for COVID-19-derived hypoxemia. However, the mechanism of hypoxemia and the role of Tocilizumab in COVID-19 need further research. Nevertheless, these findings might still assist medical workers in formulating timely treatment strategies for similar severe patients.

1 Background

Coronavirus disease 2019 (COVID-19) has been a global epidemic for nearly 2 years since its emergence in China in late 2019 [1]. However, it is still unclear if inflammation and coagulation are relevant to COVID-19-related hypoxemia [2,3], which brings challenges to clinical treatment. Tocilizumab, an IL-6 receptor blocker, is considered to be an effective treatment for COVID-19, but after recent randomized controlled trials, no definitive conclusions have been drawn [4,5]. However, IL-6 initiates the systemic pro-inflammatory response and inhibits inflammation, thus promoting cell proliferation and tissue repair [6]. Moreover, inappropriate routine use of Tocilizumab to treat COVID-19 should not be encouraged until there is insufficient evidence. Therefore, we measured IL-6, coagulation indexes, and clinical manifestations in a severe COVID-19 patient after the use of Tocilizumab (in accordance with the regulations of the National Health Commission of China) [7]. This study aimed to better understand the pathophysiology of COVID-19-related hypoxemia and improve the clinical strategy for the treatment of this disease.

2 Case report

On February 27, 2020, a 65-year-old woman was admitted to our fever clinic with symptoms of fever, cough, fatigue, and shortness of breath. She had developed fever 6 days back with a maximum temperature of 37.8°C. She did not present cold and chills before the fever. The cough started 4 days before with a small amount of white phlegm (mucus), no chest tightness, chest pain, or dyspnea. Apparent chest tightness and dyspnea began to appear on February 27, 2020, with SpO2 of 80%; Chest CT showed multiple shadows in both lungs (Figure 1b); leukocyte count was 6.58 × 109/L, absolute lymphocyte count was 0.44 × 109/L and C reactive protein (CRP) was 97.3 mg/L. The patient denied that she had been to Wuhan but had a history of contact with asymptomatic people who had returned from the COVID-19 epidemic area in Wuhan.

Figure 1 
               Changes in FiO2, P/F ratio (a), IL-6, CRP, D-dimer, PCT in a severe COVID-19 patient (a). Chest CT showed multiple shadows in both lungs on February 26 (b). X-ray showed multiple infiltrations in both lungs on March 01 (c). X-ray showed more severe infiltration 3 days before on March 04 (d). FiO2: fraction of inspiration O2; P/F ratio: SpO2/FiO2 ratio; IL-6: interleukin-6; CRP: C reactive protein; PCT: procalcitonin.
Figure 1

Changes in FiO2, P/F ratio (a), IL-6, CRP, D-dimer, PCT in a severe COVID-19 patient (a). Chest CT showed multiple shadows in both lungs on February 26 (b). X-ray showed multiple infiltrations in both lungs on March 01 (c). X-ray showed more severe infiltration 3 days before on March 04 (d). FiO2: fraction of inspiration O2; P/F ratio: SpO2/FiO2 ratio; IL-6: interleukin-6; CRP: C reactive protein; PCT: procalcitonin.

The patient was diagnosed with suspected COVID-19 virus infection and was immediately admitted to the isolation ward and kept at the prone position combined with high-flow oxygen therapy. Interferon α-2b (5 million units twice daily, atomization inhalation) and Arbidol (200 mg twice daily, orally) were prescribed as antiviral therapy, and moxifloxacin (0.4 g once daily, intravenously) was used to prevent secondary bacterial infections. Methylprednisolone (40 mg twice) was administered to attenuate the lung inflammation and a throat swab sample was taken (Table 1). Laboratory test results are listed in Table 2. On February 28, 2020 (Day 8 after the beginning of symptoms and second day of hospitalization), COVID-19 was confirmed by reverse transcription PCR performed by the Anhui Provincial Centers for Disease Control (CDC).

Table 1

Timeline of disease course according to days from initial presentation of illness and days from hospital admission

Table 2

Clinical laboratory tests

Hospital Day Day 1 Day 3 Day 4 Day 6 Day 8 Day 10 Day 11 Fever clinic
Illness Day 7 9 10 12 14 16 17 36
Measure Reference range Date
27-Feb 29-Feb 1-Mar 3-Mar 5-Mar 7-Mar 8-Mar 29-Mar
Complete blood count
  White-cell count (×109/L) 4–10 2.9 7 5.4 5.3 9.3 10.3 11 8.7
  Absolute neutrophil count (×109/L) 2.0–7.5 2.4 6.4 4.2 4.6 8.2 8.4 8.5 6.3
  Absolute Lymphocyte count (×109/L) 2.0–7.5 0.4 0.4 1.1 0.6 0.7 0.8 0.9 2
  Absolute monocyte count (×109/L) 0.12–0.8 0.1 0.1 0.1 0.6 0.3 0.3 0.3 0.4
  Red-cell count (×1012/L) 3.5–5.0 3.76 3.73 3.58 3.75 3.57 3.76 3.99 3.62
  Hemoglobin (g/L) 110–150 118 116 110 116 113 121 123 119
  Platelet count (×109/L) 100–300 168 207 215 217 212 218 221 280
Biochemical test
  Total protein (g/L) 65.0–85.0 56.8 73.4 69.9 73.5 75.6 74.3 73.9 64.1
  Albumin (g/L) 40.0–55.0 29.8 33.5 32 33.9 41.1 40.6 39.7 32.1
  Prealbumin (mg/L)
  Alanine aminotransferase (ALT) (U/L) 7–40 44 78 55 43 31 36 32 19
  Aspartate aminotransferase (AST) (U/L) 13–35 76 50 35 30 39 41 37 16
  Lactate dehydrogenase (LDH) (U/L) 135–225 438 343 328 388 559 561 511 213
  Urea (mmol/L) 2.3–7.1 3.5 6.8 6.4 5.9 4.6 4.9 4.8 2.28
  Creatinine (µmol/L) 40–130 43.4 49.8 52.3 39 43.9 44.6 44.3 41.8
  Sodium (mmol/L) 135–149 139.2 143.7 142.8 140.2 140 141 140.7 139.4
  Potassium (mmol/L) 3.5–5.3 3.87 3.53 3.22 3.36 3.84 3.76 4.02 4.64
  Chloride (mmol/L) 99–110 101.9 101.8 102.9 102 97.8 102.1 101.5 102
Arterial blood gas (ABG) analysis
  pH 7.350–7.450 7.443 7.452 7.5 7.477 7.499 7.456 7.433
  Pressure of oxygen in arterial blood (mm Hg) 83–108 76.4 80.3 61.8 79.4 63.1 89.7 98
  Pressure of carbon dioxide in arterial blood (mm Hg) 35–45 29.4 33.6 33.2 29.6 34.7 38.9 44.7
  Base excess (mmol/L) −3 to 3 −3.6 −0.4 2.6 −1.5 3.6 3.3 5.2
Coagulation profile
  Prothrombin time (s) 11–14.5 12.8 12.5 12.3 11.2 13.1 12.1 12.6
  International normalized ratio 0.8–1.25 1.11 1.08 1.06 0.96 1.13 1.04 1.09
  Fibrinogen (g/L) 1.8–4.0 6.04 4 3.24 1.99 2.43 4.57 4.33

The patient’s oxygenation index decreased gradually between the 1st and 3rd days of hospitalization. On February 29, 2020, the patient presented with a high-flow nasal cannula (HFNC) oxygen therapy (60% concentration, flow rate: 40 L/min) and partial pressure of oxygen of 80.3 mm Hg. A chest X-ray showed progressive infiltrate and diffuse gridding shadows in both lungs (Figure 1c and d). Tocilizumab 400 mg was administered intravenously. The oxygenation index between the 3rd and 8th days of hospitalization progressively decreased, while IL-6 rapidly increased to 3,775 pg/mL, and then started to slowly decrease. CRP and procalcitonin (PCT) remained at a relatively low level, but the D-dimer gradually increased, showing the same trend as the decrease of the oxygenation index. Heparin anticoagulation therapy was given on the 3rd day of hospitalization (Table 1), D-dimer gradually decreased on the 7th day of hospitalization, and the oxygenation index gradually improved on the 8th day of hospitalization. A throat swab nucleic acid detection was negative for COVID-19 on the 9th day of hospitalization (Figure 1a). On March 9, the patient was transferred to a local hospital.

  1. Informed consent: Informed consent has been obtained from all individuals included in this study.

  2. Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

3 Discussion

The dysregulation of host immune response characterized by a cytokine storm and lymphocyte depletion is a prominent manifestation of SARS-CoV-2 infection. Critically ill patients with COVID-19 are often accompanied by a significant increase in IL-6 and inflammatory cytokine storm, which are considered key factors that lead to a rapid progression of the disease and culminating in death [8]. China’s “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)” suggests that tocilizumab can be used for severe patients with increased IL-6 [7]. Tocilizumab is a monoclonal antibody against the IL-6 receptor (IL-6R). At present, this drug has been successfully used to treat a variety of chronic inflammatory diseases, such as rheumatoid arthritis, systemic and polyarticular juvenile idiopathic arthritis, and Castleman’s disease [9]. However, so far, there is no definitive evidence that Tocilizumab is effective against severe cases of COVID-19, while the relevance of the inflammatory cytokine storm in COVID-19 is still controversial [2,3,10].

In the case herein presented, the patient’s body temperature quickly dropped to normal after the use of tocilizumab; however, the respiratory function did not improve. The oxygenation index continued to decrease until March 5 before slowly increasing. Chest CT showed that bilateral lung exudation was still progressing gradually. Levels of IL-6 (pg/mL) and D-dimer (μg/mL) were increased later (from baseline of 3.1 and 3.0 to 3,114.0 and 73.70, respectively). This is similar to two cases previously reported in Chest. After tocilizumab use, IL-6 (pg/mL) and D-dimer (ng/mL) increased from 74.3 and 982 to 345 and 30,233, respectively [11].

Qin et al. [12] reported a COVID-19 patient with an IL-6 of 25 pg/mL and an acute respiratory distress syndrome(ARDS) of up to 1,618 pg/mL, which is ten times higher than that of other reported cases of COVID-19 [13]. Another study published in JAMA came to the same conclusion [14]. Besides, there are obvious differences with traditional ARDS in lung compliance and ventilation blood flow [10]. Therefore, it is suggested that the formation of microthrombus was the main reason for the decrease of oxygenation index in our reported case.

A growing number of studies have shown that the main cause of hypoxemia in COVID-19 patients is due to vasodilation that occurs upon the activation of vascular endothelial cells. This may result in pulmonary microvascular embolism; however, the effect of inflammatory factors is not obvious [7,11]. An autopsy result confirmed that there was no significant inflammatory cell infiltration in the renal interstitium despite the activation of endothelial cells and the detection of virus particles [15]. Zheng et al. [16] suggested that D-dimer is an important predictor of the prognosis of COVID-19 patients. This conclusion has been confirmed in other studies [6]. Therefore, anticoagulant therapy is considered to be an important strategy to improve the prognosis of patients with COVID-19 [2,17,18]. In our reported case, D-dimer continued to increase and was accompanied by a continuous decrease of the oxygenation index after the application of tocilizumab. After anticoagulant therapy with heparin, D-dimer decreased slowly, and the oxygenation index gradually improved. D-dimer had a significant negative correlation with the oxygenation index of the patient, suggesting that the activation of vascular endothelial cells and the formation of microthrombus were the main causes for the decrease of oxygenation index in this patient.

In this case, it was not clear whether there is a causal relationship between the use of tocilizumab and the increase of D-dimer. Previous studies have shown that IL-6 can exert different activities (pro-inflammatory and anti-inflammatory) through classic- and trans-signaling pathways [9,19]. Under steady-state conditions, the IL-6 buffer in the blood can prevent systemic IL-6 activity. Only when the blood level of IL-6 is strongly elevated and exceeds that of soluble IL-6 receptor (sIL-6R) can the trans-signaling pathway of IL-6 and systemic inflammation be activated [20,21]. Previous studies have shown that genetic deletion of the IL-6 receptor does not improve the prognosis of septic mice, while the application of soluble gp130-Fc can significantly reduce the survival rate of CLP mice, decreasing apoptosis of endothelial cells [22]. In addition, the cytokine storm contains a variety of other inflammatory factors (IL-8, IL-10, IFN-γ and MCP-1, TNF-α, IL-1, and IL-3) [23]. Blocking IL-6R with tocilizumab alone may be insufficient to improve the prognosis of COVID-19 patients.

The reported case suggests that the formation of microthrombus might be the main reason for hypoxemia; however, the mechanism of hypoxemia and the role of tocilizumab in COVID-19 need further research. Nevertheless, these findings may still assist medical workers to formulate timely treatment strategies for similarly severe patients.


These authors contributed equally to this work.

tel: +86 0553-5739731

  1. Funding information: This work was supported, in part, by the Anhui Provincial Special Project of Central Government Guiding Local Science and Technology Development of China (201907d07050001).

  2. Author contributions: W.H.L., the corresponding author, was responsible for the conceptualization of the study and the revision and approval of this manuscript. Q.C.X. and T.W. participated in the design and drafted the manuscript, collected data, and were responsible for its accuracy. All authors contributed to the data analysis and interpretation. All authors read and approved the final manuscript.

  3. Conflict of interest: The authors state no conflict of interest.

  4. Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] World Health Organization. Coronavirus disease (COVID-19) pandemic; 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019Search in Google Scholar

[2] Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7.10.1016/S2213-2600(20)30216-2Search in Google Scholar

[3] Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intens Care Med. 2020;46(6):1105–8.10.1007/s00134-020-06059-6Search in Google Scholar

[4] Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New Engl J Med. 2021;384(16):1503–16.10.1056/NEJMoa2028700Search in Google Scholar

[5] Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. New Engl J Med. 2020;383(24):2333–44.10.1056/NEJMoa2028836Search in Google Scholar

[6] Ji H, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–75.10.1152/physrev.00013.2020Search in Google Scholar

[7] Wei PF. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J. 2020;133(9):1087–95.10.1097/CM9.0000000000000819Search in Google Scholar

[8] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.10.1016/S0140-6736(20)30628-0Search in Google Scholar

[9] Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2014;27(1):21–9.10.1093/intimm/dxu081Search in Google Scholar PubMed

[10] Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Resp Crit Care. 2020;201(10):1299–300.10.1164/rccm.202003-0817LESearch in Google Scholar PubMed PubMed Central

[11] Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome. Chest. 2020;158(1):e15–9.10.1016/j.chest.2020.04.024Search in Google Scholar PubMed PubMed Central

[12] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8.10.1093/cid/ciaa248Search in Google Scholar

[13] Sinha P, Delucchi KL, McAuley DF, O’Kane CM, Matthay MA, Calfee CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–57.10.1016/S2213-2600(19)30369-8Search in Google Scholar

[14] Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically Ill patients with COVID-19 and other conditions. JAMA. 2020;324(15):1565.10.1001/jama.2020.17052Search in Google Scholar PubMed PubMed Central

[15] Su H, Yang M, Wan C, Yi L, Tang F, Zhu H, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–27.10.1016/j.kint.2020.04.003Search in Google Scholar PubMed PubMed Central

[16] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.10.1016/j.jinf.2020.04.021Search in Google Scholar PubMed PubMed Central

[17] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–73.10.1016/j.jacc.2020.04.031Search in Google Scholar PubMed PubMed Central

[18] Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del grupo de Trabajo de trombosis cardiovascular de la sociedad española de cardiología. Rev Esp Cardiol. 2020;73(9):749–57.10.1016/j.recesp.2020.04.006Search in Google Scholar PubMed PubMed Central

[19] Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015;26(5):475–87.10.1016/j.cytogfr.2015.07.004Search in Google Scholar PubMed

[20] Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–83.10.1172/JCI57158Search in Google Scholar PubMed PubMed Central

[21] Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta Mol Cell Res. 2011;1813(5):878–88.10.1016/j.bbamcr.2011.01.034Search in Google Scholar PubMed

[22] Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg R, Dorsch M, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39(6):1407–13.10.1097/CCM.0b013e318211ff56Search in Google Scholar PubMed

[23] Price LC, Garfield B, Bleakley C, Keeling A, Mcfadyen C, McCabe C, et al. Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome. Pulm Circ. 2020;10(4):765573806.10.1177/2045894020973906Search in Google Scholar PubMed PubMed Central

Received: 2021-02-02
Revised: 2021-05-28
Accepted: 2021-07-28
Published Online: 2021-08-23

© 2021 Qiancheng Xu et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Biomedical Sciences
  2. Research progress on the mechanism of orexin in pain regulation in different brain regions
  3. Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
  4. Exogenous spermidine affects polyamine metabolism in the mouse hypothalamus
  5. Iris metastasis of diffuse large B-cell lymphoma misdiagnosed as primary angle-closure glaucoma: A case report and review of the literature
  6. LncRNA PVT1 promotes cervical cancer progression by sponging miR-503 to upregulate ARL2 expression
  7. Two new inflammatory markers related to the CURB-65 score for disease severity in patients with community-acquired pneumonia: The hypersensitive C-reactive protein to albumin ratio and fibrinogen to albumin ratio
  8. Circ_0091579 enhances the malignancy of hepatocellular carcinoma via miR-1287/PDK2 axis
  9. Silencing XIST mitigated lipopolysaccharide (LPS)-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and TLR4/NF-κB signaling pathway
  10. Protocatechuic acid attenuates cerebral aneurysm formation and progression by inhibiting TNF-alpha/Nrf-2/NF-kB-mediated inflammatory mechanisms in experimental rats
  11. ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
  12. Metabolic profiling of fatty acids in Tripterygium wilfordii multiglucoside- and triptolide-induced liver-injured rats
  13. miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2
  14. Verification of neuroprotective effects of alpha-lipoic acid on chronic neuropathic pain in a chronic constriction injury rat model
  15. Circ_WWC3 overexpression decelerates the progression of osteosarcoma by regulating miR-421/PDE7B axis
  16. Knockdown of TUG1 rescues cardiomyocyte hypertrophy through targeting the miR-497/MEF2C axis
  17. MiR-146b-3p protects against AR42J cell injury in cerulein-induced acute pancreatitis model through targeting Anxa2
  18. miR-299-3p suppresses cell progression and induces apoptosis by downregulating PAX3 in gastric cancer
  19. Diabetes and COVID-19
  20. Discovery of novel potential KIT inhibitors for the treatment of gastrointestinal stromal tumor
  21. TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation
  22. circTLK1 facilitates the proliferation and metastasis of renal cell carcinoma by regulating miR-495-3p/CBL axis
  23. microRNA-9-5p protects liver sinusoidal endothelial cell against oxygen glucose deprivation/reperfusion injury
  24. Long noncoding RNA TUG1 regulates degradation of chondrocyte extracellular matrix via miR-320c/MMP-13 axis in osteoarthritis
  25. Duodenal adenocarcinoma with skin metastasis as initial manifestation: A case report
  26. Effects of Loofah cylindrica extract on learning and memory ability, brain tissue morphology, and immune function of aging mice
  27. Recombinant Bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways
  28. Blocking circ_UBR4 suppressed proliferation, migration, and cell cycle progression of human vascular smooth muscle cells in atherosclerosis
  29. Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
  30. Downregulation of circ_0037655 impedes glioma formation and metastasis via the regulation of miR-1229-3p/ITGB8 axis
  31. Vitamin D deficiency and cardiovascular risk in type 2 diabetes population
  32. Circ_0013359 facilitates the tumorigenicity of melanoma by regulating miR-136-5p/RAB9A axis
  33. Mechanisms of circular RNA circ_0066147 on pancreatic cancer progression
  34. lncRNA myocardial infarction-associated transcript (MIAT) knockdown alleviates LPS-induced chondrocytes inflammatory injury via regulating miR-488-3p/sex determining region Y-related HMG-box 11 (SOX11) axis
  35. Identification of circRNA circ-CSPP1 as a potent driver of colorectal cancer by directly targeting the miR-431/LASP1 axis
  36. Hyperhomocysteinemia exacerbates ischemia-reperfusion injury-induced acute kidney injury by mediating oxidative stress, DNA damage, JNK pathway, and apoptosis
  37. Potential prognostic markers and significant lncRNA–mRNA co-expression pairs in laryngeal squamous cell carcinoma
  38. Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development
  39. ADHFE1 is a correlative factor of patient survival in cancer
  40. The association of transcription factor Prox1 with the proliferation, migration, and invasion of lung cancer
  41. Is there a relationship between the prevalence of autoimmune thyroid disease and diabetic kidney disease?
  42. Immunoregulatory function of Dictyophora echinovolvata spore polysaccharides in immunocompromised mice induced by cyclophosphamide
  43. T cell epitopes of SARS-CoV-2 spike protein and conserved surface protein of Plasmodium malariae share sequence homology
  44. Anti-obesity effect and mechanism of mesenchymal stem cells influence on obese mice
  45. Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis
  46. Glucocorticoids protect HEI-OC1 cells from tunicamycin-induced cell damage via inhibiting endoplasmic reticulum stress
  47. Prognostic value of the neutrophil-to-lymphocyte ratio in acute organophosphorus pesticide poisoning
  48. Gastroprotective effects of diosgenin against HCl/ethanol-induced gastric mucosal injury through suppression of NF-κβ and myeloperoxidase activities
  49. Silencing of LINC00707 suppresses cell proliferation, migration, and invasion of osteosarcoma cells by modulating miR-338-3p/AHSA1 axis
  50. Successful extracorporeal membrane oxygenation resuscitation of patient with cardiogenic shock induced by phaeochromocytoma crisis mimicking hyperthyroidism: A case report
  51. Effects of miR-185-5p on replication of hepatitis C virus
  52. Lidocaine has antitumor effect on hepatocellular carcinoma via the circ_DYNC1H1/miR-520a-3p/USP14 axis
  53. Primary localized cutaneous nodular amyloidosis presenting as lymphatic malformation: A case report
  54. Multimodal magnetic resonance imaging analysis in the characteristics of Wilson’s disease: A case report and literature review
  55. Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
  56. Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
  57. Rufinamide (RUF) suppresses inflammation and maintains the integrity of the blood–brain barrier during kainic acid-induced brain damage
  58. Inhibition of ADAM10 ameliorates doxorubicin-induced cardiac remodeling by suppressing N-cadherin cleavage
  59. Invasive ductal carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia manifesting as a collision breast tumor: A case report and literature review
  60. Clonal diversity of the B cell receptor repertoire in patients with coronary in-stent restenosis and type 2 diabetes
  61. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression
  62. WDR74 promotes proliferation and metastasis in colorectal cancer cells through regulating the Wnt/β-catenin signaling pathway
  63. Down-regulation of IGHG1 enhances Protoporphyrin IX accumulation and inhibits hemin biosynthesis in colorectal cancer by suppressing the MEK-FECH axis
  64. Curcumin suppresses the progression of gastric cancer by regulating circ_0056618/miR-194-5p axis
  65. Scutellarin-induced A549 cell apoptosis depends on activation of the transforming growth factor-β1/smad2/ROS/caspase-3 pathway
  66. lncRNA NEAT1 regulates CYP1A2 and influences steroid-induced necrosis
  67. A two-microRNA signature predicts the progression of male thyroid cancer
  68. Isolation of microglia from retinas of chronic ocular hypertensive rats
  69. Changes of immune cells in patients with hepatocellular carcinoma treated by radiofrequency ablation and hepatectomy, a pilot study
  70. Calcineurin Aβ gene knockdown inhibits transient outward potassium current ion channel remodeling in hypertrophic ventricular myocyte
  71. Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma
  72. Clinical significance of activated Wnt/β-catenin signaling in apoptosis inhibition of oral cancer
  73. circ_CHFR regulates ox-LDL-mediated cell proliferation, apoptosis, and EndoMT by miR-15a-5p/EGFR axis in human brain microvessel endothelial cells
  74. Resveratrol pretreatment mitigates LPS-induced acute lung injury by regulating conventional dendritic cells’ maturation and function
  75. Ubiquitin-conjugating enzyme E2T promotes tumor stem cell characteristics and migration of cervical cancer cells by regulating the GRP78/FAK pathway
  76. Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso
  77. Protective effect of Lactobacillus-containing probiotics on intestinal mucosa of rats experiencing traumatic hemorrhagic shock
  78. Glucocorticoids induce osteonecrosis of the femoral head through the Hippo signaling pathway
  79. Endothelial cell-derived SSAO can increase MLC20 phosphorylation in VSMCs
  80. Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
  81. miR-378a-3p regulates glioma cell chemosensitivity to cisplatin through IGF1R
  82. The molecular mechanisms underlying arecoline-induced cardiac fibrosis in rats
  83. TGF-β1-overexpressing mesenchymal stem cells reciprocally regulate Th17/Treg cells by regulating the expression of IFN-γ
  84. The influence of MTHFR genetic polymorphisms on methotrexate therapy in pediatric acute lymphoblastic leukemia
  85. Red blood cell distribution width-standard deviation but not red blood cell distribution width-coefficient of variation as a potential index for the diagnosis of iron-deficiency anemia in mid-pregnancy women
  86. Small cell neuroendocrine carcinoma expressing alpha fetoprotein in the endometrium
  87. Superoxide dismutase and the sigma1 receptor as key elements of the antioxidant system in human gastrointestinal tract cancers
  88. Molecular characterization and phylogenetic studies of Echinococcus granulosus and Taenia multiceps coenurus cysts in slaughtered sheep in Saudi Arabia
  89. ITGB5 mutation discovered in a Chinese family with blepharophimosis-ptosis-epicanthus inversus syndrome
  90. ACTB and GAPDH appear at multiple SDS-PAGE positions, thus not suitable as reference genes for determining protein loading in techniques like Western blotting
  91. Facilitation of mouse skin-derived precursor growth and yield by optimizing plating density
  92. 3,4-Dihydroxyphenylethanol ameliorates lipopolysaccharide-induced septic cardiac injury in a murine model
  93. Downregulation of PITX2 inhibits the proliferation and migration of liver cancer cells and induces cell apoptosis
  94. Expression of CDK9 in endometrial cancer tissues and its effect on the proliferation of HEC-1B
  95. Novel predictor of the occurrence of DKA in T1DM patients without infection: A combination of neutrophil/lymphocyte ratio and white blood cells
  96. Investigation of molecular regulation mechanism under the pathophysiology of subarachnoid hemorrhage
  97. miR-25-3p protects renal tubular epithelial cells from apoptosis induced by renal IRI by targeting DKK3
  98. Bioengineering and Biotechnology
  99. Green fabrication of Co and Co3O4 nanoparticles and their biomedical applications: A review
  100. Agriculture
  101. Effects of inorganic and organic selenium sources on the growth performance of broilers in China: A meta-analysis
  102. Crop-livestock integration practices, knowledge, and attitudes among smallholder farmers: Hedging against climate change-induced shocks in semi-arid Zimbabwe
  103. Food Science and Nutrition
  104. Effect of food processing on the antioxidant activity of flavones from Polygonatum odoratum (Mill.) Druce
  105. Vitamin D and iodine status was associated with the risk and complication of type 2 diabetes mellitus in China
  106. Diversity of microbiota in Slovak summer ewes’ cheese “Bryndza”
  107. Comparison between voltammetric detection methods for abalone-flavoring liquid
  108. Composition of low-molecular-weight glutenin subunits in common wheat (Triticum aestivum L.) and their effects on the rheological properties of dough
  109. Application of culture, PCR, and PacBio sequencing for determination of microbial composition of milk from subclinical mastitis dairy cows of smallholder farms
  110. Investigating microplastics and potentially toxic elements contamination in canned Tuna, Salmon, and Sardine fishes from Taif markets, KSA
  111. From bench to bar side: Evaluating the red wine storage lesion
  112. Establishment of an iodine model for prevention of iodine-excess-induced thyroid dysfunction in pregnant women
  113. Plant Sciences
  114. Characterization of GMPP from Dendrobium huoshanense yielding GDP-D-mannose
  115. Comparative analysis of the SPL gene family in five Rosaceae species: Fragaria vesca, Malus domestica, Prunus persica, Rubus occidentalis, and Pyrus pyrifolia
  116. Identification of leaf rust resistance genes Lr34 and Lr46 in common wheat (Triticum aestivum L. ssp. aestivum) lines of different origin using multiplex PCR
  117. Investigation of bioactivities of Taxus chinensis, Taxus cuspidata, and Taxus × media by gas chromatography-mass spectrometry
  118. Morphological structures and histochemistry of roots and shoots in Myricaria laxiflora (Tamaricaceae)
  119. Transcriptome analysis of resistance mechanism to potato wart disease
  120. In silico analysis of glycosyltransferase 2 family genes in duckweed (Spirodela polyrhiza) and its role in salt stress tolerance
  121. Comparative study on growth traits and ions regulation of zoysiagrasses under varied salinity treatments
  122. Role of MS1 homolog Ntms1 gene of tobacco infertility
  123. Biological characteristics and fungicide sensitivity of Pyricularia variabilis
  124. In silico/computational analysis of mevalonate pyrophosphate decarboxylase gene families in Campanulids
  125. Identification of novel drought-responsive miRNA regulatory network of drought stress response in common vetch (Vicia sativa)
  126. How photoautotrophy, photomixotrophy, and ventilation affect the stomata and fluorescence emission of pistachios rootstock?
  127. Apoplastic histochemical features of plant root walls that may facilitate ion uptake and retention
  128. Ecology and Environmental Sciences
  129. The impact of sewage sludge on the fungal communities in the rhizosphere and roots of barley and on barley yield
  130. Domestication of wild animals may provide a springboard for rapid variation of coronavirus
  131. Response of benthic invertebrate assemblages to seasonal and habitat condition in the Wewe River, Ashanti region (Ghana)
  132. Molecular record for the first authentication of Isaria cicadae from Vietnam
  133. Twig biomass allocation of Betula platyphylla in different habitats in Wudalianchi Volcano, northeast China
  134. Animal Sciences
  135. Supplementation of probiotics in water beneficial growth performance, carcass traits, immune function, and antioxidant capacity in broiler chickens
  136. Predators of the giant pine scale, Marchalina hellenica (Gennadius 1883; Hemiptera: Marchalinidae), out of its natural range in Turkey
  137. Honey in wound healing: An updated review
  138. NONMMUT140591.1 may serve as a ceRNA to regulate Gata5 in UT-B knockout-induced cardiac conduction block
  139. Radiotherapy for the treatment of pulmonary hydatidosis in sheep
  140. Retraction
  141. Retraction of “Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating microRNA-34a-5p/NOTCH1 signaling pathway”
  142. Special Issue on Reuse of Agro-Industrial By-Products
  143. An effect of positional isomerism of benzoic acid derivatives on antibacterial activity against Escherichia coli
  144. Special Issue on Computing and Artificial Techniques for Life Science Applications - Part II
  145. Relationship of Gensini score with retinal vessel diameter and arteriovenous ratio in senile CHD
  146. Effects of different enantiomers of amlodipine on lipid profiles and vasomotor factors in atherosclerotic rabbits
  147. Establishment of the New Zealand white rabbit animal model of fatty keratopathy associated with corneal neovascularization
  148. lncRNA MALAT1/miR-143 axis is a potential biomarker for in-stent restenosis and is involved in the multiplication of vascular smooth muscle cells
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/biol-2021-0088/html
Scroll to top button